Objective: To investigate the correlation of the mRNA expression levels of human equilibria ve nucleo-side transporter 1 ( hENT1) with clinicopathological parameters in patients with non - small cell lung cancer receiving gemcitabine - based chemotherapy as well as their clincal prognostic significance. Methods: The relative mRNA expression of hENTl to the internal reference gene (3 - actin in formalin - fixed paraffin - embeded non - small cell lung cancer tumor specimens was measured using real - time quantitative reverse transcription polymerase chain reaction. And the relationship between hENT1 levels with clinicopathological parameters and survival in non - small cell lung cancer was studied. Results: hENT1 expression levels were detected in all tumor specimens. hENTl expression was not related to clinicopathological parameters in non - small cell lung cancer. Though from multivariate analysis, hENTl mRNA hypoexpression was not a significantly favorable factor for overall survival (P = 0.707), and for time to progression (P =0.420) .there was a tendency that patients with high hENT1 mRNA levels had a significant longer median time to overall survival and progression. Although from Cox proportional hazards model for survival, hENT1 mRNA hypoexpression was not a significantly favorable factor for OS and PFS,tumor lymph node matastasis was an independent predictive marker of overall survival of non - small cell lung cancer( P = 0.02 ). Conclusion: Intratumoral hENT1 mRNA expression level was not associated with clinicopathological parmeters, maybe a predictive marker of survival of gemcitabine - containing combination chemotherapy in non - small cell lung cancer. It can provide critical information for planning personalized chemotherapy. Tumor lymph node matastasis was an independent predictivemarker of survival of non - small cell lung cancer.%目的:探讨非小细胞肺癌(NSCLC)石蜡组织中平衡型核苷转运载体(human equilibritive nucleoside transporter 1,hENT1)mRNA表达水平与接受吉西他滨方案化疗的患者临床病理关系及预后意义.方法:采用实时荧光定量RT - PCR方法检测福尔马林固定-石蜡包埋的非小细胞肺癌组织中hENT1 mRNA表达水平,并比较其表达水平与接受吉西他滨化疗的患者临床病理及生存期之间的关系.hENT1 mRNA表达水平与非小细胞肺癌患者的临床及肿瘤病理特征无相关性.结果:hENT1 mRNA高表达组患者经含吉西他滨方案化疗后中位无进展生存期17.5月、总生存期36月,两组间无进展生存期(P =0.420)、总生存期(P=0.707).但是从生存曲线分析,hENT1 mRNA高表达的NSCLC患者可能从吉西他滨治疗中获益,可能获得更长无进展生存期的趋势.COX多因素回归分析显示TNM分期与肺癌患者总生存期(P=0.02)、无进展生存期(P =0.008)显著相关.hENT1 mRNA表达水平与非小细胞肺癌肿瘤病理特征无相关性,可能与肿瘤恶性生物学行为无关.结论:hENT1 mRNA的表达水平可能是含吉西他滨药物化疗的NSCLC患者预后的影响因素,肿瘤组织的分期可能是影响NSCLC患者预后的独立预测因素.
展开▼
